Recent articles for private investors with a focus on dividend announcements
Shire Q3 2011 results
Angus Russell, Chief Executive Officer, commented:"Shire has delivered another strong set of quarterly results. Total product sales were up 28% to $1,018 million, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of$50 million in the quarter. We're on track to deliver significant 2011 earnings growth.Sales of our rare disease treatments were very strong: with VPRIV up 31% and REPLAGAL up 40% versus the same quarter in 2010. FIRAZYR, our self-administered treatment for acute attacks of Hereditary Angioedema, was approved by the FDA in August and launched just a few weeks ago; initial demand from patients has been positive. This week we have also initiated a rolling Biologics License Application for REPLAGAL in the US, designated Fast Track by the FDA.The US ADHD market continues to grow and with a strong `back to school'season, our portfolio of treatments has gained share. VYVANSE sales were up 32% and INTUNIV sales grew 50%.The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world. In addition to initiating Phase 3 clinical trials for VYVANSE as adjunctive therapy in Major Depressive Disorder (MDD), we're releasing highlights of exploratory data showing that cognition and executive function were improved in patients with MDD taking VYVANSE as adjunctive therapy. We've also released positive new clinical data related to our Phase 3 European ADHD clinical program. Overall, we've increased investment in our R&D programs by 21% compared to Q3 2010, and still generated good earnings growth and strong cashflows.Over the course of the year we've seen market expectations for Shire's 2011 earnings rise, with further increases in the last quarter. After these good third quarter results, and after taking account of the lower royalty income that we will be recording in future periods, we remain on track to meet these increased expectations. We anticipate that this will be another very good year for Shire as we deliver strong sales and continue our investment program for sustained future growth."
Hammerson sells stake in O'Parinor
Hammerson confirms that it has agreed to exercise the option to sell a further 24% interest in O'Parinor shopping centre, Aulnay-sous-Bois, near Paris to a client of Rockspring Property Investment Managers LLP ("Rockspring"). The sale was envisaged following the original disposal last year of a 51% stake in the property.
WPP Q3 Results
"In the first nine months of 2011, reported revenues were up 7.1% at £7.170 billion, up 12.9% in US dollars to $11.573 billion and up 5.2% in Euros to €8.225 billion. In constant currencies, revenues were up 8.2%, chiefly reflecting the weakness of the pound sterling against most major currencies. On a like-for-like basis, excluding the impact of acquisitions and currency fluctuations, revenues were up 5.6% and the more relevant gross margin up 6.4%."
AstraZeneca 3rd Quarter results
Revenue for the third quarter declined by 2 percent at constant exchange rates (CER) to $8,213 million.
Royal Dutch Shell 3rd Quarter 2011 figures - dividend announced
ROYAL DUTCH SHELL PLC 3RD QUARTER 2011 UNAUDITED RESULTS
Kazakhmys Q3 production statement and IMS
Kazakhmys PLC Production Report for the Third Quarter Ended 30 September 2011 and Interim Management Statement
U.S. Market observations
After three up days, US stocks fell sharply on Wall Street during Tuesday, with investors nervous ahead of the euro summit and after a gauge of consumer confidence fell to a more than two-year low. The Dow fell 200 points at one point but recovered
Balfour Beatty Contract win
Balfour Beatty, the international infrastructure group, announces today that it has been awarded the £77.6 million M4/M5 managed motorways scheme construction contract, near Bristol, by the Highways Agency who manage, maintain and improve England's motorways and trunk roads.
Glaxo third quarter 2011 results - boost dividend 6%
GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%
International Power trading statement
"Revenue for the nine months ended 30 September 2011 was E12,344 million. Our enlarged portfolio of assets has continued to perform well and in line with our expectations. We continue to expect growth in 2011 with performance in the second half anticipated to be similar to the first half, despite the current economic backdrop."
Aggreko Trading Statement
"On an underlying basis (in constant currency and excluding the one-off impact of the FIFA World Cup as well as pass-through fuel), 3Q revenue grew by 22%. Headline revenue increased by 13%." Looking ahead, "Although the prospects for the global economy remain uncertain, the strength of our recent trading performance, and our view of the prospects for the fourth quarter, mean that we now believe that pre-tax profits for the year will be at least £320M. This represents underlying growth in profits for the year of over 24%."
Precis of Dividend Investing Article
This is an extract from an article written by Michael Clarke who is the manager of Fidelity's money builder dividend fund.
Precis of Dividend article on Interactive Investor International
Similar to the times article the other day. This was on III today
Precis of Questor column in the daily telegraph
Yesterdays Questor column (05/10/20011) highlighted the attraction of Global companies with higher yields. Now, questor does not have our level of knowledge when it comes to dividends, but it is worth pointing out what the column highlighted.The first point for us to make is that all of the companies mentioned in the artcle are in our investment tools at www.dividendmax.com
Precis of Dividend article in the times
An article appeared in the times today entitled 'Rising Dividends put a wry smile on investors faces'
G4S Aquisition and Rights Issue
Shares in G4S (GFS) fell 13% as it announced a £5.2 billion acquisition of ISS. There will be a £2 billion rights issue.
AMEC wins BP contract
BP and it's partners has appointed Engineering and project management giant AMEC to work on the main platform design for Clair Ridge, the second phase of the giant Clair oil field, west of Shetland.
The work is valued at £150 million and follows on from AMEC's successful completion of the conceptual engineering studies and the define phase of the Clair Ridge project. All are part of BP's existing global agreement with AMEC.
The award will see AMEC deliver detail design, follow-on engineering, site support, plus procurement, supply chain services, materials management and information management services for the whole project. The work will be carried out by a combined team of 600 technical experts based in AMEC's London offices.
"As well as creating hundreds of UK jobs, the development will help to ensure jobs in the industry and the UK's energy security in the future,” said Neil Bruce, chief operating officer of AMEC.
7401-7428 of 7428
